Cargando…

Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder

BACKGROUND: There is growing evidence that disturbances in cholesterol metabolism may be involved in major depressive disorder (MDD). However, it is not known if cholesterol metabolites present in the brain and periphery can be used to diagnose and predict an MDD patient’s response to antidepressant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Zuoli, Yang, Jian, Zhou, Jia, Zhou, Jingjing, Feng, Lei, Feng, Yuan, He, Yi, Liu, Min, Li, Yuhong, Wang, Gang, Li, Rena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Archival Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593904/ https://www.ncbi.nlm.nih.gov/pubmed/37881566 http://dx.doi.org/10.1016/j.bpsgos.2023.01.004

Ejemplares similares

Development and Internal Validation of a Novel Model to Identify Inflammatory Biomarkers of a Response to Escitalopram in Patients With Major Depressive Disorder
por: Zhou, Jingjing, et al.
Publicado: (2021)

Brain-Specific Oxysterols and Risk of Schizophrenia in Clinical High-Risk Subjects and Patients With Schizophrenia
por: Sun, Zuoli, et al.
Publicado: (2021)

Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder
por: Wang, Yaping, et al.
Publicado: (2023)

Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2023)

Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial
por: Zhou, Jingjing, et al.
Publicado: (2019)

Effects of escitalopram therapy on resting-state functional connectivity of subsystems of the default mode network in unmedicated patients with major depressive disorder
por: Cui, Jian, et al.
Publicado: (2021)

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder
por: Zhang, Shudong, et al.
Publicado: (2023)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

Reduced Plasma Levels of α-Klotho and Their Correlation With Klotho Polymorphisms in Elderly Patients With Major Depressive Disorders
por: Gao, Xiang, et al.
Publicado: (2021)

Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression
por: Bandu, Raju, et al.
Publicado: (2023)

Identifying the Common Genetic Basis of Antidepressant Response
por: Pain, Oliver, et al.
Publicado: (2021)

Genome-wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium()
por: Power, Robert A., et al.
Publicado: (2017)

Delineating the Genetic Component of Gene Expression in Major Depression
por: Dall’Aglio, Lorenza, et al.
Publicado: (2021)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

Oxysterols in the pathogenesis of major chronic diseases()
por: Poli, Giuseppe, et al.
Publicado: (2013)

Increased Aperiodic Neural Activity During Sleep in Major Depressive Disorder
por: Rosenblum, Yevgenia, et al.
Publicado: (2022)

Treatment of alcohol dependence in patients with co-morbid major depressive disorder – predictors for the outcomes with memantine and escitalopram medication
por: Muhonen, Leea H, et al.
Publicado: (2008)

Galanin(1-15) Potentiates the Antidepressant-like Effects Induced by Escitalopram in a Rat Model of Depression
por: García-Durán, Laura, et al.
Publicado: (2021)

Antidepressant Response and Stress Resilience Are Promoted by CART Peptides in GABAergic Neurons of the Anterior Cingulate Cortex
por: Funayama, Yuki, et al.
Publicado: (2022)

Efficacy of escitalopram for poststroke depression: a systematic review and meta-analysis
por: Feng, Rong-fang, et al.
Publicado: (2022)

Identifying Subgroups of Major Depressive Disorder Using Brain Structural Covariance Networks and Mapping of Associated Clinical and Cognitive Variables
por: Yang, Xiao, et al.
Publicado: (2021)

Antidepressant Medication Use and Risk of Hyperglycemia and Diabetes Mellitus—A Noncausal Association?
por: Kivimäki, Mika, et al.
Publicado: (2011)

Vascular Risk Status as a Predictor of Later-Life Depressive Symptoms: A Cohort Study
por: Kivimäki, Mika, et al.
Publicado: (2012)

Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression
por: Leonard, Brian, et al.
Publicado: (2010)

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
por: Singh, A B, et al.
Publicado: (2012)

Brain arousal regulation as response predictor for antidepressant therapy in major depression
por: Schmidt, Frank M., et al.
Publicado: (2017)

Label-Free Liquid Chromatography–Mass Spectrometry Proteomic Analysis of the Urinary Proteome for Measuring the Escitalopram Treatment Response From Major Depressive Disorder
por: Huan, Yuhang, et al.
Publicado: (2021)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

A Combined Pathway and Regional Heritability Analysis Indicates NETRIN1 Pathway Is Associated With Major Depressive Disorder
por: Zeng, Yanni, et al.
Publicado: (2017)

Alterations in the Serum Proteome Following Electroconvulsive Therapy for a Major Depressive Episode: A Longitudinal Multicenter Study
por: Göteson, Andreas, et al.
Publicado: (2022)

Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder: A Pilot Randomized Clinical Trial
por: Xiao, Chunfeng, et al.
Publicado: (2023)

Clinical efficacy and safety of Guipi decoction combined with escitalopram oxalate tablets in patients with depression
por: Yu, Jia, et al.
Publicado: (2023)

Differential effects of antidepressants escitalopram versus lithium on Gs alpha membrane relocalization
por: Donati, Robert J, et al.
Publicado: (2015)

Predicting the Naturalistic Course of Major Depressive Disorder Using Clinical and Multimodal Neuroimaging Information: A Multivariate Pattern Recognition Study
por: Schmaal, Lianne, et al.
Publicado: (2015)

3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
por: Avram, Speranta, et al.
Publicado: (2010)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
por: Bernini de Brito, Rodrigo, et al.
Publicado: (2020)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0djq7cn6j2ml3hih10mum700d0